Injection-Site Cutaneous Pseudolymphoma Induced by a GM-CSF-Producing Tumor Cell Vaccine

JAMA Dermatol. 2017 Apr 1;153(4):332-334. doi: 10.1001/jamadermatol.2016.4988.

Authors

Karl Staser¹, Sabra Abner², Milan Anadkat¹, Amy Musiek¹, András Schaffer³

Affiliations

¹ Division of Dermatology, Department of Medicine, Washington University, St Louis, Missouri.
² Department of Pathology and Immunology, Washington University, St Louis, Missouri.
³ Division of Dermatology, Department of Medicine, Washington University, St Louis, Missouri2Department of Pathology and Immunology, Washington University, St Louis, Missouri3Dermatopathololgy Center, Washington University, St Louis, Missouri.

PMID: 28114617
DOI: 10.1001/jamadermatol.2016.4988

No abstract available

Publication types

Case Reports

MeSH terms

Biopsy
Cancer Vaccines / administration & dosage
Cancer Vaccines / adverse effects*
Humans
Injections / adverse effects
Male
Middle Aged
Pseudolymphoma / chemically induced*
Pseudolymphoma / diagnosis
Skin / drug effects
Skin / pathology
Skin Diseases / chemically induced*
Skin Diseases / diagnosis
Young Adult

Substances

Cancer Vaccines
GVAX vaccine